Impedimed Limited · ASX:IPD
Impedimed — Shareholder Meeting (November 2021)
24 slides from Impedimed's shareholder meeting presentation, Nov 10, 2021
Slide 1: 2021 Annual General Meeting – CEO's Presentation
10 November 2021 ASX ANNOUNCEMENT 2021 Annual General Meeting – CEO’s Presentation ImpediMed Limited (ImpediMed) (ASX: IPD) provides the attached CEO’s presentation to be delivered at today’s Annual General Meeting commencing at 9.00am AEDT. The webcast of the AGM can be joined at: www.agmlive.link/
Slide 2: Forward-Looking Statements
Forward-Looking Statements This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we
Slide 3: AGM Presentation November 2021 – SOZO Digital Health Platform
AGM PRESENTATION NOVEMBER 2021 ® SOZO Digital Health Platform ü Technology ü Transformation ü Adoption ü Affirmation Growth
Slide 4: Disclaimer Forward Looking Statements
Disclaimer Forward Looking Statements • The material contained in this document is a presentation of general information about the • Certain statements in this presentation may constitute forward-looking statements or activities of ImpediMed Limited (“ImpediMed”) current as at the date of this prese
Slide 5: Our Transformation
Our Transformation Medical Device Connected Digital Health Platform U400 BIS Device SOZO Platform U400 Cancer Population^ SOZO® Cancer Population^ • ~20 Minute Test • Less than 30 Second Test • Trained Nurse/Therapist • Medical Assistant • Standalone Device • Connected Device • Gel Backed Electrodes
Slide 6: Comprehensive Data
Comprehensive Data SOZO® measures and tracks critical patient data • L-Dex® lymphoedema index • HF-DexTM heart failure index • Total body water • Protein and minerals • Extracellular fluid • Basal metabolic rate • Intracellular fluid • Phase angle • Skeletal muscle mass • Body mass index • Fat mass
Slide 7: Connected Digital Health Platform
Connected Digital Health Platform Test patients at any location and allows data access and sharing across the entire healthcare system Cloud Access Scalable Test patients at any location Add and move test locations and immediately review without any additional software results online setup Trends Se
Slide 8: SOZO Digital Health Platform Device, Multiple Applications
® SOZO Digital Health Platform 1 Device, Multiple Applications Lymphoedema FDA Clearance, CE Mark Heart Failure FDA Clearance, CE Mark End Stage Renal Disease* CE Mark Protein Calorie Malnutrition FDA Clearance, CE Mark Body Composition FDA Clearance, CE Mark Bone Density^ Venous Insufficiency^^ * k
Slide 9: Platform Technology: Initial Focus on Three Large Overlapping Markets
Platform Technology: Initial Focus on Three Large Overlapping Markets Critical is the ability to accurately measure small shifts in $2.0+ Billion fluid and tissue Annual Addressable Market • Cardiovascular disease is the leading cause of death among people on dialysis with kidney disease • Dialysis
Slide 10: Strong Adoption, Validated Technology
Strong Adoption, Validated Technology 810+ 410+ SOZO Devices in SOZO Devices in Core Business Clinical Business 35 2 international drug studies involving 410+ sites 28 countries evaluating fluid volumes in (heart failure & renal failure patients) Proprietary, do not reproduce, distribute, or excerpt
Slide 11: Summary of Achievements Since Last AGM
Summary of Achievements Since Last AGM Total Revenue of $8.4 million in FY21, an increase of 46% year-over-year, which resulted in a $10 million Annual Run Rate based on Q4 FY’21 revenue. Business now fully funded: Completed a $35 million Placement to new and existing institutional and sophisticated
Slide 12: 2021 Financial Year Results
2021 Financial Year Results SOZO Revenue Patient Tests To-Date $10m+ $8.4m (Excluding Legacy) (261,000+ on File) $8,000,000 130,000 Annual Revenue Total Revenue Run Rate +46% YOY ✓ RECORD YEAR $6,000,000 97,500 90%+ SaaS Gross Margins $12m+ $7.6m Total Contract Value SOZO Revenue $4,000,000 65,000 s
Slide 13: Inflection point with identifiable growth drivers
Inflection point with identifiable growth drivers • Transformation to Connected Digital Health Platform complete • $10m annual revenue run rate with strong growth despite COVID-19 headwinds • Multiple applications addressing significant health care needs • ~$48m in cash after capital raising^ • Comp
Slide 14: PREVENT driving Lymphoedema and Oncology adoption
PREVENT driving Lymphoedema and Oncology adoption PREVENT Trial Successful, Statistically Significant Consistent Reduction in Lymphoedema Progression Study after Study • PREVENT trial showed 92% of patients with early detection of cancer- related lymphoedema using L-Dex and intervention did not prog
Slide 15: Growth Drivers: Reimbursement & NCCN Guidelines
Growth Drivers: Reimbursement & NCCN Guidelines® Reimbursement NCCN® • PREVENT randomised control trial the key to reimbursement • NCCN Submission upon PREVENT publication and accelerating growth • Current NCCN submission covering the Meta-Analysis and • PREVENT delivers clear path to reimbursement
Slide 16: Heart Failure Commercialisation Underway
Heart Failure Commercialisation Underway SOZO® Heart Failure Patient Output • Heart Failure affects at least 26 million people worldwide • Costs US healthcare system estimated $31 billion annually • Assessment of fluid burden is critical to HF patients • Current methods of determining fluid levels a
Slide 17: Renal Failure Accelerated with FDA Breakthrough Designation
Renal Failure Accelerated with FDA Breakthrough Designation • There are in excess of 450,000 US dialysis patients receiving treatment three times a week • More than 85% of these treatments will be performed in dialysis centres • Very attractive concentrated market with two companies caring for 85% o
Slide 18: Completion of Expected Milestones from the 2020 AGM
Completion of Expected Milestones from the 2020 AGM Majority of the goals achieved: Lymphoedema ü Continued strong growth in SOZO® SaaS subscription-based business ü Meta-analysis published ü Publication of additional scientific papers • Private payors begin coverage of L-Dex — catalyst for broad ad
Slide 19: Summary of Focus Areas for 2022
Summary of Focus Areas for 2022 Continue growth in sales and adoption of SOZO®. CORP. Complete SOZO II development for Heart Failure and Renal Failure indications. Launch software Version 5.0 with data and software enhancements focused on corporate accounts. Publish the PREVENT Trial manuscript in a
Slide 20: Appendix
—- Appendix
Slide 21: Share Purchase Plan (SPP) – Offer timetable
Share Purchase Plan (SPP) – Offer timetable Event Date (AEDT) Record Date 7.00pm on Tuesday, 26 October 2021 Date used to determine Eligible Shareholders Opening Date 9.00am on Wednesday, 3 November 2021 Offer under SPP opened Closing Date 5.00pm on Thursday, 11 November 2021 Offer under SPP closes
Slide 22: Management Team
Richard Carreon Managing Director and Chief Executive Officer • Joined July 2012 Management Team • 30+ years experience • Extensive experience in the medical device field Deep and Broad Commercialisation Experience • and growth companies Previously Vice President at Medtronic (10 years) Frank Vicini
Slide 23: Board of Directors
Board of Directors 21 Scott R. Ward Donald A. Williams David Anderson Richard Carreon Judith Downes Robert M. Graham Amit R. Patel MS, BSc BAcy, CPA BSc Managing Director and BA(Hons), DipEd, AO, FAA, FAHMS, MBBS, MD, MBA, BME Non-Executive Chairman Non-Executive Director Non-Executive Director Chie
Slide 24: Contact Details
Contact Details Investor Relations: Mike Bassett SVP Corporate and Strategic Development mbassett@impedimed.com +61 407 431 432 www.impedimed.com